Stereotactic radiation therapy (SBRT) has become the standard therapy for non-operative treatment of early stage lung cancer. In centrally located tumors the appropriate dose and fractionation is not known. RTOG 0813 has studied this question in a dose escalation study. We sought to report our institutional experience at the highest dose level of 12 Gy × 5. We retrospectively reviewed the full records of patients treated with SBRT for central lung tumors (<2 cm of the carina) with IRB approval. Patients included both primary NSCLC as well patients with recurrence following surgery and/or conventional radiation therapy. All patients, underwent 4D-CT simulation and treatment planning was done with IMRT or VMAT techniques. Dose fractionation was 12 Gy × 5 prescribed to the 95% of the PTV. RTOG normal tissue constraints were used, with the exception of that no constraints were placed on the trachea or major airways. All patients were followed with PET/CT at 2 months and CT or PET at 3-4 month intervals thereafter. 71 patients, between 5/09 to 4/13, were treated. Median age was 71, 88% had biopsy proven disease. 33 patients had undergone previous thoracic radiation therapy and 15 had prior thoracic resection. . The median lesion diameter was 2.8 cm (Max 8 cm) and the median GTV volume was 13.59 cc (Max 372 cc). With a median follow-up time of 21 months the local control rate is 97%. At two months 46% had a metabolic CR, 37% had metabolic PR and 19% had stable disease on PET. 7% of patients developed radiation pneumonits, (no grade 4 or 5 events). One patient who had previous surgery and radiation therapy developed esophageal bleeding after SBRT 4 months after treatment that was fatal. Overall survival is 24 months (95% CI 18.8: 27.3). SBRT is safe and effective at the 12 Gy × 5 dose level for central lung lesions. Local control and response are highly encouraging.